clinical trial · NCT06155084
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Metastatic Castration-resistant Prostate CancerHP518 - Dose EscalationHP518 - Dose EscalationHP518 -Dose Expansion
brief summary
The overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of patients with progressive mCRPC in dose-escalation phase
started
Dec 26, 2023
primary completion
Mar 1, 2026
completion
Sep 1, 2026
last updated
Dec 22, 2025
detailed description
This First in Human dose escalation and expansion study of HP518 in patients with progressive mCRPC after NHA and chemotherapy is being conducted not only to evaluate the safety and tolerability of orally administered HP518, but also to provide preliminary efficacy for the reference of future studies.
official title
A Phase I/II Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer in China
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol